Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRN’s Dickinson on ephedra ban

This article was originally published in The Tan Sheet

Executive Summary

Trade group president maintains FDA's Dec. 30 announcement of its intention to ban ephedrine alkaloid-containing supplements proves the agency has the authority to remove products presenting an "unreasonable risk" from the marketplace under DSHEA. In an editorial/opinion published in the Jan. 8 USA Today, Annette Dickinson, PhD, appluads FDA Commissioner Mark McClellan, MD/PhD, for exercising the agency's "enforcement power actively." She also disputes arguments that DSHEA does not work because until now, it has not been fully put into practice. "Consumers would be better served by the FDA's continued enforcement of existing law than by Congress' taking a sledgehammer to the law when the most that is needed is a chisel," Dickinson concludes...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel